HWP
ANTX icon

Highline Wealth Partners’s AN2 Therapeutics ANTX Stock Holding History

Highline Wealth Partners’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$6.35K – 1074
2025
Q3 		$6.35K Hold
5,000
– – ﹤0.01% 514
2025
Q2 		$5.3K Buy
+5,000
New +$5.96K ﹤0.01% 434

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highline Wealth Partners's ANTX Position: Q4 2025 in Review

Highline Wealth Partners sold out of AN2 Therapeutics (ANTX) in Q4 2025, closing a stake of 5,000 shares — an estimated $6.35K sold.

Highline Wealth Partners first reported a position in ANTX in Q2 2025 and held it in 2 quarters. The position peaked at $6.35K in Q3 2025. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2025.

  • Highline Wealth Partners reported no remaining AN2 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Highline Wealth Partners sold 5,000 AN2 Therapeutics shares in Q4 2025, an estimated $6.35K.
  • Highline Wealth Partners first reported a position in AN2 Therapeutics in Q2 2025 and held it in 2 quarters.
  • Highline Wealth Partners's AN2 Therapeutics position peaked at $6.35K in Q3 2025.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2025.

Based on Highline Wealth Partners's 13F filing for Q4 2025, filed 15 Jan 2026.